Primary Malignant Fibrous Histiocytoma of Proximal Humerus with Pathological Fracture- Case Report

Malkesh D. Shah¹, Ajinkya Arun Naik¹*, Sai Sabharish Reddy¹ and Sarvang M. Desai¹

¹Department of Orthopaedics, Smt. B. K. Shah Medical Institute and Research Center, Sumandeep Vidyapeeth Deemed to be University, India.

Authors’ contributions

This work was carried out in collaboration among all authors. Author MDS Conception and critical revision of the article. Author AAN Data collection and Drafting the article. Author SSR Data analysis. Author SMD Final approval of the version to be published. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i32A31728

Editor(s):
(1) Dr. Rafik Karaman, Al-Quds University, Palestine.

Reviewers:
(1) Andrei Zbuchea, District Emergency Hospital, Romania.
(2) Swapnil Anil Keny, Maharashtra University of Health sciences, India.

Complete Peer review History: http://www.sdiarticle4.com/review-history/70078

Received 10 April 2021
Accepted 16 June 2021
Published 18 June 2021

ABSTRACT

Malignant fibrous histiocytoma (MFH) is a tumor of late adulthood that occurs in men more commonly than women. Proximal humerus involvement in PMFH is comparatively rare. A 45 year old female presented with complain of pain and mild swelling over the left shoulder with restricted range of movement since 15 days. Radiography of the affected part was suggestive of an osteolytic eccentric lesion with a pathological fracture. A trucut needle biopsy showed minimal tumour tissue with abundant necrosis and showed giant cells with pleomorphic mononuclear cells. So intralesional curettage followed by osteosynthesis with PHILLOS plating and bone cementing was done. Intra operative specimen sent for histopathological examination showed presence of fibroblast cells arranged in storiform pattern s/o MFH along with occasional multinucleated giant cells. Postoperatively patient was started with adjuvant chemotherapy. Patient had good results functionally and clinically with no signs of recurrence till follow up of 1.5 years.
Keywords: Malignant fibrous histiocytoma (MFH); proximal humerus pathological fracture with osteolytic lesion; malignant fibrous histiocytoma of bone.

1. INTRODUCTION

Malignant fibrous histiocytoma (MFH) is a tumor of late adulthood that occurs in men more commonly than women.1 But its osseous counterpart is an unusual entity, accounting for less than 2% of all primary malignant tumors [1]. Primary osseous MFH (PMFH) is a centrally located lesion found in the diaphyseal or metaphyseal region of the bone that causes aggressive bone destruction and a soft tissue mass. [2] PMFH is found in the extremities 70–75% of the time with about 50% of the cases in the lower extremities.3 The common sites in order are the distal femur, proximal tibia and proximal femur. MFH was reported as somatic soft tissue sarcoma in many studies but bony involvement is relatively rare [3].

Proximal humerus involvement in PMFH is comparatively rare. Pathological fracture is noted in 20% of all patients with MFH of bone at the first presentation [4]. Here, we report a rare case of PMFH of the proximal humerus and its management, presenting with a pathological fracture along with osteolytic lesion.

2. CASE PRESENTATION

A 45 year old female presented with complain of pain and mild swelling over the left shoulder since 15 days. Patient gives history of a trivial trauma 10 days after the onset of the above complaints. A thorough clinical examination revealed slight swelling and tenderness of the proximal aspect of the left upper arm, restricted and painful movements of left shoulder, without vascular and neurological involvement. All preoperative routine blood investigations were within normal limits. Radiography of the affected part was suggestive of an osteolytic eccentric lesion with a pathological fracture [Fig. 1]. A trucut needle biopsy was done, which showed minimal tumour tissue with abundant necrosis and degenerative changes. Sections studies showed giant cells and pleomorphic mononuclear cells. Patient was diagnosed provisionally with a possibility of giant cell tumour. Based on the trucut needle biopsy, patient underwent surgical intervention in form of intralesional curettage followed by osteosynthesis with PHILLOS plating and bone cementing [Fig. 2]. Intra operative specimen was sent for histopathological examination, which showed presence of fibroblast cells arranged in storiform pattern along with occasional multinucleated giant cells [Fig. 3]. These cells showed mild to moderate pleomorphism with 3-4/10 HPF of mitoses. Immunohistochemistry study showed positive for CD68. Biopsy report confirmed the diagnosis of MFH with low malignant potential. Post-operatively, patient was immobilize for 2 weeks in shoulder arm pouch with immobilizer after which gradual physiotherapy for up to 6 months was given to achieve good functional range of movement of shoulder. This intra operative biopsy report was different from the initial biopsy taken pre operatively. Thereafter patient was referred to a higher centre for adjuvant chemotherapy and was followed up regularly every 3 months to examine for any signs of recurrence or metastasis. We managed patient with adjuvant postop chemotherapy and followed this patient till 1.5 years, showing no clinical or radiological signs of any recurrence. Patient showed good radiological and functional results with no sign of recurrence or metastases at final follow-up of 1.5 years [Figs. 4 and 5].

PRE OP X RAY

Fig. 1. Preoperative radiograph of left proximal humerus AP and lateral views showing an osteolytic eccentric lesion with a pathological fracture
Fig. 2. Postoperative radiograph of left proximal humerus AP and lateral views showing intralesional curettage followed by osteosynthesis with PHILLOS plating and bone cementing

HISTOPATHOLOGY REPORT

Fig. 3. Intra operative specimen showing presence of fibroblast cells arranged in storiform pattern along with occasional multinucleated giant cells

LAST FOLLOW UP X RAY

Fig. 4. Last follow up at 1.5 years postoperative radiograph of left proximal humerus AP and lateral views showing united pathological fracture of left proximal humerus
3. DISCUSSION

MFH usually presents with a soft tissue mass with or without cortical erosion [5]. Radiologically, MFH is an aggressive, permeative lesion, which often lacks distinctive features found in other high-grade primary bone malignancies [6]. There is not normally a periosteal reaction. MRI is very helpful for MFH in local staging as well as surgical planning because it assesses the degree of intramedullary extension (and dimensions) and invasion of the adjacent physeal plates, joints, muscle compartments and neurovascular bundles [7].

18F-FDG PET/CT has high sensitivity, specificity and accuracy for MFH based on the semiquantitative measurements of the glucose consumption and also it felt to be an extremely useful tool for the detection of bone metastases and recurrence [8]. But in this case as patient due to financial issue didn’t undergo for such investigations.

MFH classification showed a broad range of histological appearances and consisted of 5 subtypes: storiform, pleomorphic, myxoid, giant cell and inflammatory [9]. The mainstay treatment for MFH-B is preoperative chemotherapy followed by wide resection with adjuvant chemotherapy [10]. Chemotherapy reduces the tumor bulk and increases the chances of a limb sparing procedure. Prognosis depends on local recurrence and metastases. The prognosis of MFH becomes worse as a lesion is larger and deeper in the soft tissue. MFH metastasizes to the lungs, lymph nodes, liver and bone [11]. In several studies postoperative radiation therapy has been recommended for patients in postoperative histological evaluation [12]. In current case, interestingly due to contradictory biopsy report, we initially treated patient as giant cell tumor and later we treated patient postoperatively with adjuvant chemotherapeutic agents (Methotrexate + Adriaamycin) for MFH and using this protocol, remissions are achieved significantly with better functional improvement. Combination of Intralesional curettage and adjuvant chemotherapy appears to be the most promising and easily managed at rural level where there is unavailability of radiation and related high cost therapies. The prognosis of MFH of bone is poor with having reported 5-year survival rate of 38.3% [13]. The surgical management in relatively younger age group were associated with a better prognosis as compared to older age group having comorbidities [14]. Bone tumours have variable biological behaviour with prognosis depending on local or distant recurrence and metastases [15]. The other review of the literature reveals different rates of metastases and local recurrences between 30-70% [16]. Several studies reported that due to adjuvant chemotherapy the chances of local or metastatic diseases shows gradual reduction. As certain studies shown that intralesional surgery have high chances of local recurrence and metastatic possibilities but we still didn’t report any recurrence or metastases in this case [17]. Some studies also reported that adjuvant radiation therapy is not as effective as chemotherapy [18]. In the present report, the lower rate of metastasis was due to the effectiveness of chemotherapy [19]. As the patient was last followed up till 1.5 years, we require a minimum 5 years of follow up to rule out recurrence so as to assess survival rate.

FOLLOW UP MOVEMENTS

Fig. 5. Final follow up at 1.5 years postoperative showing full range of motion of left shoulder joint
4. CONCLUSION

MFH treated with a surgery and adjuvant chemotherapy without radiotherapy can also give satisfactory outcome. We also conclude that current approach for low malignant MFH showed good results functionally as well as clinically with no signs of recurrence. Therefore, consideration can be made to administer chemotherapy in addition to intralesional curettage in order to improve survival rates in low PMFH without radiation.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

ACKNOWLEDGEMENT

Authors acknowledge the immense help received from the scholars whose articles are cited and included in references of this manuscript. The authors are also grateful to authors / editors / publishers of all those articles, journals and books from where

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Franchi A. Epidemiology and classification of bone tumors. Clinical Cases in mineral and bone metabolism. 2012;9(2):92.
2. Subramanian S, Viswanathan VK. Lytic Bone Lesions. StatPearls [Internet]; 2019.
3. Joo M, Lee GJ, Koh YC, Kwon OK, Park YK. Primary intraosseous malignant fibrous histiocytoma of the skull: A case report. Journal of Korean medical science. 2003;18(4):609.
4. Zuo D, Zheng L, Sun W, Hua Y, Cai Z. Pathologic fracture does not influence prognosis in stage IIB osteosarcoma: A case–control study. World journal of surgical oncology. 2013;11(1):1-9.
5. Subhawong TK, Fishman EK, Swart JE, Carrino JA, Attar S, Fayad LM. Soft-tissue masses and masslike conditions: What does CT add to diagnosis and management?. American Journal of Roentgenology. 2010;194(6):1559-67.
6. Nascimento D, Suchard G, Hatem M, de Abreu A. The role of magnetic resonance imaging in the evaluation of bone tumours and tumour-like lesions. Insights into imaging. 2014;5(4):419-40.
7. Nascimento D, Suchard G, Hatem M, de Abreu A. The role of magnetic resonance imaging in the evaluation of bone tumours and tumour-like lesions. Insights into imaging. 2014;5(4):419-40.
8. Lin CY, Chen JH, Liang JA, Lin CC, Jeng LB, Kao CH. 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: A systematic review and meta-analysis. European journal of radiology. 2012;81(9):2417-22.
9. Chamale JB, Bruno M, Mandojana F, José L, Armando L, Alejandro D. Malignant fibrous histiocytoma in the right portion of the mandible with metastasis in pancreas. International journal of surgery case reports. 2017;41:71-5.
10. Öz Kurt B, Başarır K, Yıldız YH, Kalem M, Sağlık Y. Primary malignant fibrous histiocytoma of long bones: Long-term follow-up. Joint Diseases and Related Surgery. 2016;27(2):094-9.
11. Chen KH, Chou TM, Shieh SJ. Management of extremity malignant fibrous histiocytoma: A 10-year experience. Formosan Journal of Surgery. 2015;48(1):1-9.
12. Vasileios KA, Eward WC, Brigman BE. Surgical treatment and prognosis in patients with high-grade soft tissue malignant fibrous histiocytoma of the extremities. Archives of orthopaedic and trauma surgery. 2012;132(7):955-61.
13. Malik AT, Baek J, Alexander JH, Voskuil RT, Khan SN, Scharschmidt TJ. Malignant fibrous histiocytoma of bone: A survival analysis from the National Cancer Database. Journal of surgical oncology. 2020;121(7):1097-103.
14. Picci P, Bacci G, Ferrari S, Mercuri M. Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors. Annals of oncology. 1997;8(11):1107-15.
15. Atik OŞ, Ayañoğlu T, Atalar H, Yörübulut M. One patient, one bone, and two
different tumoral lesions. Joint Diseases and Related Surgery. 2016;27(1):051-3.
16. Bacci G, Avella M, Picci P, Dallari D, Malaguti C, Biagini R, et al. Primary chemotherapy and delayed surgery for malignant fibrous histiocytoma of bone in the extremity. Tumori Journal. 1990;76(6):537-42.
17. Jebson PJ, Sullivan L, Murray PM, Athanasian EA. Malignant fibrous histiocytoma of the distal radius: a case report. The Journal of hand surgery. 2004;29(2):194-200.
18. Lehnhardt M, Daigeler A, Homann HH, Schweiberer V, Goertz O, et al. Kuhnen C, Steinau HU. MFH revisited: Outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities—an analysis of 140 patients. Langenbeck's archives of surgery. 2009;394(2):313-20.
19. Bramwell VH, Steward WP, Nooij M, Whelan J, Craft AW, Grimer RJ, Taminau AH, Cannon SR, Malcolm AJ, Hogendoorn PC, Uscinska B. Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: a European Osteosarcoma Intergroup study. Journal of clinical oncology. 1999;17(10):3260-9.

© 2021 Shah et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sdiarticle4.com/review-history/70078